Aileron Therapeutics, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US00887A2042

USD

1.14

-0.14 (-10.94%)

Feb 05

NAS

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sunshine Biopharma, Inc.

Xenetic Biosciences, Inc.

Inhibikase Therapeutics, Inc.

Aileron Therapeutics, Inc.

Tenax Therapeutics, Inc.

Lexaria Bioscience Corp.

Pulmatrix, Inc.

Protagenic Therapeutics, Inc.

Titan Pharmaceuticals, Inc.

Oragenics, Inc.

Galera Therapeutics, Inc.

Why is Aileron Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Aileron Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Aileron Therapeutics, Inc.

-47.95%

-0.58

99.80%

S&P 500

13.99%

0.81

19.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

1.60%

EBIT to Interest (avg)

-24.47

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.15

Sales to Capital Employed (avg)

Tax Ratio

2.46%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

39.56%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.89

EV to EBIT

-1.39

EV to EBITDA

-1.39

EV to Capital Employed

0.87

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-62.46%

ROE (Latest)

-48.66%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -12.32 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-2What is not working for the Company

CASH AND EQV(HY)

Lowest at USD 13.15 MM

DEBT-EQUITY RATIO (HY)

Highest at -11.92 %

Here's what is working for Aileron Therapeutics, Inc.

Net Profit

Higher at USD -12.32 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Aileron Therapeutics, Inc.

Cash and Eqv

Lowest at USD 13.15 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -11.92 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio